logo
Google Reviews Logo

317.636.6481

One Indiana Square, Suite 1400 Indianapolis, Indiana 46204

Make a Payment
logo
CONTACT US
CALL US
  • Home
  • Firm Overview
  • Our Attorneys
  • Practice Areas
    • Pharmaceutical Drug & Medical Device Litigation
    • Personal Injury
    • Sexual Abuse
    • Class Action
    • Medical Malpractice
    • Eminent Domain
    • Family Law
    • Business Services, Real Estate & Business Litigation
    • Bankruptcy, Creditor’s Rights, & Commercial & Business Law
    • Appellate Law
  • Firm News
    • News & Announcements
    • Alerts
  • Resources
    • Video Library
    • Blog
  • Contact Us
Google Reviews Logo

317.636.6481

One Indiana Square, Suite 1400 Indianapolis, Indiana 46204

Make a Payment
  • Home
  • Firm Overview
  • Our Attorneys
  • Practice Areas
    • Pharmaceutical Drug & Medical Device Litigation
    • Personal Injury
    • Sexual Abuse
    • Class Action
    • Medical Malpractice
    • Eminent Domain
    • Family Law
    • Business Services, Real Estate & Business Litigation
    • Bankruptcy, Creditor’s Rights, & Commercial & Business Law
    • Appellate Law
  • Firm News
    • News & Announcements
    • Alerts
  • Resources
    • Video Library
    • Blog
  • Contact Us

Home » FDA Warns of Increased Risk of Death with Tygacil Use

FDA Warns of Increased Risk of Death with Tygacil Use

The FDA has issued a black box warning for Pfizer’s antibacterial drug Tygacil due to an increased risk of death associated with the use of this intravenous medication. Tygacil is used to treat patients with complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP). Serious side effects may include irregular heartbeat, severe stomach and abdominal pain, blurred vision, and severe diarrhea which can occur weeks after treatment.

The FDA analyzed data from 10 clinical trials and found a higher risk of death among patients receiving Tygacil compared to other antibacterial drugs. This safety communication includes instruction to healthcare providers stating that Tygacil should only be used in situations when alternative treatments are not suitable. More information about this warning can be found on the FDA website.

If you or someone you care about has been prescribed Tygacil and suffered a serious injury, contact us. Our product liability attorneys have litigated thousands of product liability claims against pharmaceutical companies and medical device manufacturers and can advise you of your legal rights and options.

One Indiana Square Suite 1400
Indianapolis, Indiana 46204

Copyright ©  Cohen & Malad, LLP. All rights reserved.

Disclaimer  |  Privacy Policy

 

Schedule a free consultation Today
  • This field is for validation purposes and should be left unchanged.

Schedule a free consultation Today

  • This field is for validation purposes and should be left unchanged.

ALERTS

Former NFL Players Still Have Time to Claim Concussion Settlement Funds

It’s not too late for former National Football League players to claim their funds from the concussion .. Read More

SEE ALL ALERTS

In the News

Indiana Legal Services and Indiana State Bar Foundation Receive $90,000 donation from Cohen & Malad, LLP Class Action United Way of Central Indiana’s Center for Working Families Receives $32,000 from Cohen & Malad, LLP Settlement Funds Indianapolis Neighborhood Housing Partnership Receives $32,000 from Cohen & Malad, LLP Settlement Funds
READ OUR NEWS